Inflammatory bowel diseases (IBD) are complex and multifactorial diseases that require a differentiated and evolving treatment approach. When monotherapies reach their limits, the need for combination strategies grows. The focus is on both conventional combination regimens and innovative applications of dual biological (targeted) therapies.
Partner
Autoren
- PD Dr. med. Pascal Juillerat
- Prof. Dr. med. Stephan Brand
Publikation
- GASTROENTEROLOGIE PRAXIS
Related Topics
You May Also Like
- Chronically active MS lesions
New paradigm in the diagnosis and treatment of multiple sclerosis
- AI in neurology
Control instead of a flood of data: AI makes big data and wearables usable
- Participation of the patient
Adherence in psychiatry
- Eosinophilic esophagitis
EoE rarely occurs in isolation
- Lung cancer with EGFR mutation
New perspectives in first-line therapy
- Sleep disorder
Sleep medicine in transition: new goals and a reassessment of old hypnotics
- Ginkgo biloba extract in the Alzheimer's mouse model
Effects on disease-associated microglia subpopulations
- "Patients W.A.I.T Indicator"